Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the U.S. FDA has approved Restylane Contour for the correction of temple hollowing in patients over the age of 21.
Germany needs new talent for its labor market — and fresh ideas to ensure that foreign workers not only come, but also stay.